About Aziyo Biologics
Aziyo Biologics is a publicly listed company based in Silver Spring (United States) founded in 2015. Regenerative medicine products are developed for orthopedic and cardiovascular applications. Aziyo Biologics has raised $49.59 million across 6 funding rounds from investors including HighCape Capital, Deerfield and Birchview Capital. The company has 162 employees. Its chief executive, as recorded, is Ron Lloyd. Aziyo Biologics offers products and services including CanGaroo, SimpliDerm, and EluPro. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is AZIYO BIOLOGICS, INC. Its competitors include Theradaptive, MiMedx Group and Cardival Medical; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2015 and based in Silver Spring, United States, regenerative medicine products are developed by Aziyo Biologics for use in orthopedic, cardiovascular, and other medical specialties. Natural healing mechanisms are leveraged in these products to support clinical applications across multiple sectors. Operations focus on innovation within the biotechnology field, with an emphasis on therapeutic solutions for diverse medical needs.
- Total Equity Funding$49.59M (USD)
in 6 rounds
- InvestorsHighCape Capital
& 2 more
- Employee Count162
Products & Services of Aziyo Biologics
Aziyo Biologics offers a comprehensive portfolio of products and services, including CanGaroo, SimpliDerm, and EluPro.
Secures implants like pacemakers to prevent migration and aid healing.
Used for soft tissue repair in reconstruction procedures.
Optimizes stability for cardiac implantable electronic devices.
Funding Insights of Aziyo Biologics
Aziyo Biologics has successfully raised a total of $49.59M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $49.59M
- Total Rounds 6
- First Round $19.5M
(Jun 2015)
- Investors Count 3
All 6 funding rounds of Aziyo Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | Post-IPO | – | – | ||
| Sep 2020 | $5.04M | Series C | – | – | – |
| Dec 2019 | $3.05M | Series B | – | – | – |
| Jul 2018 | $10M | Series B | – | – | – |
| Jun 2017 | $12M | Series B | – | HighCape Capital | – |
| Jun 2015 | $19.5M | Series B | – | Deerfield | – |
3 investors in total: 3 institutional.
Investors in Aziyo Biologics
Aziyo Biologics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include HighCape Capital, Deerfield and Birchview Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science companies are targeted for private equity investments. | 2013 | highcape.com | New York, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Business growth and value creation are facilitated by Birchview Capital. | 2021 | birchviewcapital.ca | Canada |
Investor details for Aziyo Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aziyo Biologics
26 people are tracked at Aziyo Biologics (10 in leadership, 5 in board & advisors, 11 in team); the tracked headcount is 162.
| Name | Role | Group |
|---|---|---|
Ron Lloyd | CEO | Leadership |
Sonali Fonseca | VP & General Manager, Orthobiologics & Emerging Business | Leadership |
Courtney Guyer | VP & General Manager, Women’s Health | Leadership |
Michelle Williams | Chief Scientific Officer | Leadership |
C. Randal Mills | President & CEO | Leadership |
Matthew Ferguson | Chief Financial Officer | Leadership |
Shawn LOfficial, PhD | Senior Director, Medical and Clinical Affairs | Leadership |
Dana Yoo | Vice President of Research and Development | Leadership |
Kris Mahota | Director Of Finance | Leadership |
Kyle Farrell | Vice President Sales | Leadership |
Maybelle Jordan | Board Member | Board & advisors |
David Colpman | Board Member | Board & advisors |
Brigid A. Makes | Board Member | Board & advisors |
W. Matthew Zuga | Board Member | Board & advisors |
Kevin Rakin | Chairman | Board & advisors |
Jeff Hamet | SVP, Finance | Team |
Tom Spencer | Regional Sales Manager | Team |
Thomas Spencer | Sales Specialist | Team |
Elizabeth Regan | Accounting Supervisor | Team |
Jill Kimos | Corporate Accounting Manager | Team |
6 more people are available in the full profile.
Complete people profiles for Aziyo Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aziyo Biologics
4 dated milestones of Aziyo Biologics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Aziyo Biologics is founded.
- Funding First funding round of $19.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of Aziyo Biologics
Aziyo Biologics has 3 listed competitors in our database, 2 of them funded. They include Theradaptive, MiMedx Group and Cardival Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| theradaptive.com | 2004 | Boston, United States | $32.2M | 21 | Therapeutic delivery platform is developed for orthopedic clinical indications. | |
| mimedx.com | 1985 | Marietta, United States | 735 | Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | ||
| cardivamedical.com | 2002 | Santa Clara, United States | $169.45M | 158 | A device for vascular access management is developed. |
Detailed competitors of Aziyo Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aziyo Biologics
Websites that share an audience with Aziyo Biologics (aziyo.com).
Websites whose visitors overlap most with Aziyo Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| elutia.com | 100% | 2.7K | #6,239,711 | View details |
Top companies in Orthopedics
3 companies that operate in the same segment as Aziyo Biologics (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aziyo Biologics
Complete news archive for Aziyo Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aziyo Biologics
Aziyo Biologics was founded in 2015.
Aziyo Biologics is headquartered in Silver Spring, United States. It is registered at Silver Spring, Maryland, United States.
Ron Lloyd is the CEO of Aziyo Biologics, as recorded in our data.
Aziyo Biologics is a funded company, having raised a total of $49.59M across 6 funding rounds to date. The company's 1st funding round was a Series B of $19.5M, raised on Jun 2015.
Aziyo Biologics has 162 employees.
Founded in 2015 and based in Silver Spring, United States, regenerative medicine products are developed by Aziyo Biologics for use in orthopedic, cardiovascular, and other medical specialties. Natural healing mechanisms are leveraged in these products to support clinical applications across multiple sectors. Operations focus on innovation within the biotechnology field, with an emphasis on therapeutic solutions for diverse medical needs.
Aziyo Biologics's top competitors include Theradaptive, MiMedx Group and Cardival Medical.
Aziyo Biologics offers CanGaroo, SimpliDerm, and EluPro.
Aziyo Biologics has 3 investors. Key investors include HighCape Capital, Deerfield, and Birchview Capital.
Aziyo Biologics operates through Aziyo Biologics, Inc..